Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Expert Rev Vaccines. 2013 Dec;12(12):1395-416. doi: 10.1586/14760584.2013.845531. Epub 2013 Oct 30.
The highly attenuated poxvirus strain modified vaccinia virus Ankara (MVA) has reached maturity as a vector delivery system and as a vaccine candidate against a broad spectrum of diseases. This has been largely recognized from research on virus-host cell interactions and immunological studies in pre-clinical and clinical trials. This review addresses the studies of MVA vectors used in phase I/II clinical trials, with the aim to provide the main findings obtained on their behavior when tested against relevant human diseases and cancer and also highlights the strategies currently implemented to improve the MVA immunogenicity. The authors assess that MVA vectors are progressing as strong vaccine candidates either alone or when administered in combination with other vectors.
高度减毒的痘病毒安卡拉株（MVA）已作为载体传递系统和针对广泛疾病的候选疫苗而成熟。这在病毒-宿主细胞相互作用的研究以及临床前和临床试验中的免疫学研究中已得到广泛认可。这篇综述探讨了 MVA 载体在 I/II 期临床试验中的应用研究，旨在提供在针对相关人类疾病和癌症进行测试时获得的主要发现，并强调了当前实施的提高 MVA 免疫原性的策略。作者评估认为，MVA 载体作为单独使用或与其他载体联合使用的强大候选疫苗正在不断发展。
